I. Au-marché-en-france and .. , Impact des données de vie réelle dans l'evaluation des medicaments : en France et en Europe 58 A. Les données de vie réelle au service de l'accès, p.58

N. Garrison, Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report, Value in Health, vol.10, issue.5, pp.326-335, 2007.
DOI : 10.1111/j.1524-4733.2007.00186.x

D. Pouvourville-et-mongrédien and «. , accès au marché remboursé pour les médicaments : les contrats de partages de risques fondés sur les résultats, 2016.

C. Pajares-y-sanchez, CESE : prix et accès aux traitements médicamenteux innovants » 6 https, 2017.

M. Planel, « Le prix des médicaments en question(s) », 10 https://www.has-sante.fr/portail/upload/docs/application/pdf/2014- 12/dossier_presse_evaluation_medico_eco.pdf 11 https, 2017.

L. Annemans and M. Aristides, Real-Life Data: A Growing Need ISPOR connection uniting science and practice 15 http://solidarites-sante.gouv.fr/ministere/acteurs/instances-rattachees/article/ceps-comiteeconomique-des-produits-de-sante, 2007.

R. Gliklich and N. D. , Registries for Evaluating Patient Outcomes: A User's Guide, Agency for Healthcare Research and Quality, pp.1-235, 2007.

G. Salines and C. , D Launay « les cohortes : intérêt, rôles et position de l'InVS

C. L. Galès and A. E. Hasnaoui, Evaluation des médicaments après la commercialisation : efficacité réelle, population exposée et impact sur la santé publique, Thérapie, vol.58, pp.210-219, 2003.

M. Berger, Good practices for real?world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR?ISPE Special Task Force on real?world evidence in healthcare decision making " , Value in health, p.4297, 1002.

L. Placé, gouvernement.fr/action/l-ouverture-des-donnees-publiques 30 https, p.31, 2016.

P. V. Bonanno and . Kremers, Adaptive pathways: possible next steps for payers in preparation for their potential implementationMethods to analyze real-world databases and registries " Bulletin of the NYU Hospital for Joint Diseases, Frontiers in Pharmacology, vol.33, pp.193-197, 2009.

C. Lusignan, Creating and using real-world evidence to answer questions about clinical effectiveness, Journal of Innovation in Health Informatics, vol.22, issue.3, pp.368-373, 2015.
DOI : 10.14236/jhi.v22i3.177

. Launois, Le médicament, quel suivi en Vie Réelle ? " , 8 ème forum Patient PFIZER, 2015.

. Maisonneuve, Donn??es de vie r??elle et recherche clinique??: le compl??ment des donn??es des essais randomis??s???, La Presse M??dicale, vol.44, issue.6, 2015.
DOI : 10.1016/j.lpm.2015.02.005

G. Atelier-de, Table ronde N° 6 -Ateliers de Giens XX, « Modélisation et essais cliniques en pédiatrie

T. Lasky, In the Real-World, Kids Use Medications and Devices, Drugs - Real World Outcomes, vol.16, issue.1, pp.75-78, 2017.
DOI : 10.1186/s12888-016-1041-0

. Palanca-maresca, SENTIA: a systematic online monitoring registry for children and adolescents treated with antipsychotics, SpringerPlus, vol.3, issue.1, p.187, 2014.
DOI : 10.1016/j.euroneuro.2011.04.001

L. Garrison, Performance-Based Risk-Sharing Arrangements???Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force, Value in Health, vol.16, issue.5, pp.703-719, 2013.
DOI : 10.1016/j.jval.2013.04.011

S. Jaros?awski, Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts, BMC Health Services Research, vol.11, issue.1, p.259, 2011.
DOI : 10.1016/S1470-2045(09)70402-4

. Ferrario, Managed entry agreements for pharmaceuticals: The European experience " , LSE research online 48 http://www.arcat-sante.org/infos-cles/hepatites/les-donnees-de-la-vraie-vie-des-cohortes, p.2, 2013.

D. Polton, Les données de vie réelle, un enjeu majeur pour la qualité des soins et la régulation du système de santé : l'exemple du médicament, 2017.

K. Pawels, Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future, Frontiers in Pharmacology, vol.5, p.56, 2017.
DOI : 10.1016/S1470-2045(15)00449-0

S. Montilla, MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY, International Journal of Technology Assessment in Health Care, vol.3, issue.4, pp.210-213, 2015.
DOI : 10.1017/S0266462315000446

. Garattini, Risk sharing agreements: What lessons from Italy?, International Journal of Technology Assessment in Health Care, vol.27, issue.02, pp.169-72, 2011.
DOI : 10.1093/annonc/mdq097

M. Prada, Managed Entry Agreements for orphan drugs in Italy active on, 2016.

. Russo, Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers, Annals of Oncology, vol.1136, issue.1, p.61, 2010.
DOI : 10.1196/annals.1425.007

J. Espin, Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines EmiNet 62 https://www.abpi.org.uk/what-we-do/pricing-regulation/pharmaceutical-price-regulation-schemepprs, p.2, 2011.

. Coulton, PHP15 RISK-SHARING SCHEMES WORLDWIDE: A LANDSCAPE ANALYSIS OF HEALTH OUTCOMES-BASED REIMBURSEMENT AGREEMENTS, Value in Health, vol.13, issue.7, 2010.
DOI : 10.1016/S1098-3015(11)73223-5

J. Darba, The Spanish Ministry of Health initiates a new financing model for high-cost medicines in the areas of rare diseases and oncology Article LinkedIn : (lien : https://www.linkedin.com/pulse/spanish-ministry-health-initiates-new-financing-model-josep- darb%C3%A0, 2018.

M. Molimard and M. Bamberger, ??tudes post-AMM : apport dans la r??inscription des produits, Th??rapie, vol.64, issue.3, pp.203-207, 2009.
DOI : 10.2515/therapie/2009029

L. Guigue and C. Et-richard, Le Big data en Sant?? pr??figure-t-il la ?? m??decine 3.0 ?? ?, HEGEL - HEpato-GastroEnt??rologie Lib??rale, vol.4, issue.3, pp.273-278, 2014.
DOI : 10.4267/2042/54093

. Bastien, http://www.lebigdata.fr/big-data-transforme-soins-de-sante Le Big Data transforme les soins de santé, 2016.